Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODIGE 18)

被引：0
作者：
Bennouna, J. [1 ]
Hiret, S. [2 ]
Borg, C. [3 ]
Bertaut, A. [4 ]
Bouche, O. [5 ]
Deplanque, G. [6 ]
Francois, E. [7 ]
Conroy, T. [8 ]
Ghiringhelli, F. [9 ]
des Guetz, G. [10 ]
Seitz, J-F. [11 ]
Artru, P. [12 ]
Stanbury, T. [13 ]
Charpentier, S. [14 ]
Denis, M. [14 ]
Adenis, A. [15 ]
机构：
[1] CHU Nantes, IMAD Digest Oncol, Nantes, France
[2] Inst Cancerol Ouest, Med Oncol, St Herblain, France
[3] CHU Besancon, Med Oncol, Besancon, France
[4] Georges Francois Leclerc Canc Ctr, Biostat, Dijon, France
[5] CHU Reims, Gastroenterol, Reims, France
[6] Hop Riviera Chablais, Med Oncol, Vevey, Switzerland
[7] Ctr Antoine Lacassagne, Med Oncol, Nice, France
[8] Inst Cancerol Lorraine, Med Oncol, Vandoeuvre Les Nancy, France
[9] Georges Francois Leclerc Canc Ctr, Med Oncol, Dijon, France
[10] CHU St Denis, Med Oncol, Limoges, France
[11] APHM, Gastroenterol, Marseille, France
[12] Hop Prive Jean Mermoz, Gastroenterol, Lyon, France
[13] UNICANCER, Invest Ctr, Paris, France
[14] CHU Nantes, Mol Biol, Nantes, France
[15] Ctr Oscar Lambret, Med Oncol, Lille, France
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
477O
引用
收藏
页数：2
相关论文
共 50 条
  • [41] ECONOMIC EVALUATION OF FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (MCRC) BASED ON IRINOTECAN (FOLFIRI) plus BEVACIZUMAB OR CETUXIMAB, ADJUSTED BY KRAS GENE (WILD-TYPE (WT) OR MUTANT (MT))
    Torrecillas, L.
    Vargas, J.
    VALUE IN HEALTH, 2008, 11 (06) : A469 - A470
  • [42] Prognostic factors in KRAS wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with biweekly cetuximab (C) plus irinotecan, fluorouracil, and leucovorin (FOLFIRI): A phase II study
    Personeni, Nicola
    Rimassa, Lorenza
    Verusio, Claudio
    Barni, Sandro
    Destro, Annarita
    Raschioni, Carlotta
    Armenia, Silvia
    Floriani, Irene
    Gerardi, Chiara
    Monteforte, Marta
    Villa, Eugenio
    Bozzarelli, Silvia
    Roncalli, Massimo
    Torri, Valter
    Labianca, Roberto
    Santoro, Armando
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [43] A randomized phase II study comparing oral S-1 plus 24-hour infusion of irinotecan (Iri) and bevacizumab (Bev) with FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer (MCRC).
    Sadahiro, Sotaro
    Suzuki, Toshiyuki
    Tanaka, Akira
    Okada, Kazutake
    Saito, Gota
    Miyakita, Hiroshi
    Ogimi, Takashi
    Chan, Lin Fung
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [44] Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naive Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer
    Yoshino, Takayuki
    Uetake, Hiroyuki
    Tsuchihara, Katsuya
    Shitara, Kohei
    Yamazaki, Kentaro
    Oki, Eiji
    Sato, Takeo
    Naitoh, Takeshi
    Komatsu, Yoshito
    Kato, Takeshi
    Yamanaka, Kazunori
    Iwasaki, Kouji
    Soeda, Jumpei
    Hihara, Masamitsu
    Yamanaka, Takeharu
    Ochiai, Atsushi
    Muro, Kei
    CLINICAL COLORECTAL CANCER, 2017, 16 (02) : 158 - 163
  • [45] PANITUMUMAB AFTER PROGRESSION ON CETUXIMAB IN PATIENTS WITH KRAS WILD-TYPE METASTATIC COLORECTAL CANCER (MCRC): A SINGLE INSTITUTION EXPERIENCE
    Marino, Antonella
    Caliolo, Chiara
    Sponziello, Francesco
    Nacci, Angelo
    Quaranta, Annamaria
    Mazzoni, Enrica
    Rizzo, Pietro
    Calvani, Nicola
    Orlando, Laura
    Schiavone, Paola
    Fedele, Palma
    D'Amico, Maria
    Cinefra, Margherita
    Cinieri, Saverio
    ANNALS OF ONCOLOGY, 2012, 23 : 95 - 96
  • [46] PHASE II STUDY OF IRINOTECAN PLUS CETUXIMAB FOR PRETREATED METASTATIC COLORECTAL CANCER WITH KRAS WILD TYPE
    Shitara, Kohei
    Yokota, Tomoya
    Takahari, Daisuke
    Ura, Takashi
    Inaba, Yoshitaka
    Yamaura, Hidekazu
    Sato, Yozo
    Najima, Mina
    Kawai, Hiroki
    Tajika, Masahiro
    Sawaki, Akira
    Yatabe, Yasushi
    Utsunomiya, Setsuo
    Muro, Kei
    ANNALS OF ONCOLOGY, 2010, 21 : 13 - 13
  • [47] Phase II study of panitumumab with irinotecan for patients with KRAS wild-type metastatic colorectal cancer (MCRC) refractory to standard chemotherapy: A GERCOR study
    Chibaudel, B.
    Tournigand, C.
    Mabro, M.
    Bennamoun, M.
    Artru, P.
    Nguyen, S.
    Bachet, J.
    Aissat, N.
    Blons, H.
    Laurent-Puig, P.
    De Gramont, A.
    Andre, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [48] Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial
    Cremolini, Chiara
    Malmorino, Federica
    Bergamo, Francesca
    Aprile, Giuseppe
    Salvatore, Lisa
    Masi, Gianluca
    Dell'Aquila, Emanuela
    Antoniotti, Carlotta
    Murgioni, Sabina
    Allegrini, Giacomo
    Borelli, Beatrice
    Gemma, Donatello
    Casagrande, Mariaelena
    Granetto, Cristina
    Delfanti, Sara
    Di Donato, Samantha
    Schirripa, Marta
    Sensi, Elisa
    Tonini, Giuseppe
    Lonardi, Sara
    Fontanini, Gabriella
    Boni, Luca
    Falcone, Alfredo
    EUROPEAN JOURNAL OF CANCER, 2019, 109 : 175 - 182
  • [49] Phase II Study of Panitumumab With Irinotecan for Patients With KRas Wild-type Metastatic Colorectal Cancer (MCRC) Refractory to Standard Chemotherapy - a GERCor Study
    Andre, T.
    Chibaudel, B.
    Mabro, M.
    Bennamoun, M.
    Artru, P.
    Bachet, J. B.
    Hadengue, A.
    Blons, H.
    Laurent-Puig, P.
    de Gramont, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S435 - S435
  • [50] Efficacy and safety of bevacizumab (BEV)-based combination regimens in patients with metastatic colorectal cancer (mCRC): Randomized phase II study of BEV plus FOLFIRI versus BEV plus XELIRI (FNCLCC ACCORD 13/0503 study)
    Ducreux, M.
    Adenis, A.
    Mendiboure, J.
    Francois, E.
    Boucher, E.
    Chauffert, B.
    Ychou, M.
    Pierga, J.
    Montoto-Grillot, C.
    Conroy, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345